Weekly Paclitaxel After Failure of Gemcitabine in Pancreatic Cancer Patients with Malignant Ascites: A Retrospective Study

ArticleinJapanese Journal of Clinical Oncology 40(12):1135-8 · December 2010with10 Reads
Impact Factor: 2.02 · DOI: 10.1093/jjco/hyq117 · Source: PubMed


    Peritoneal metastasis is one of the major sites of disease progression of pancreatic cancer. There have been few trials in the second-line setting after gemcitabine failure because patients can hardly be candidates for chemotherapy after failure in the first-line chemotherapy, especially those with malignant ascites. The safety and efficacy of weekly paclitaxel therapy was evaluated for pancreatic cancer patients with malignant ascites in this retrospective study.
    The subjects of this retrospective study were 23 advanced pancreatic cancer patients with malignant ascites who received weekly paclitaxel therapy after gemcitabine failure. Paclitaxel (80 mg/m(2), div. for 1 h) was administered on Days 1, 8 and 15, every 4 weeks.
    While the disease control rate was 35%, decrease of ascites was obtained in 30% of the patients and ascites control rate was 61%. The median survival time was 101 days. Toxicities were mild, although one treatment-related death occurred.
    Weekly paclitaxel therapy may be useful treatment option for pancreatic cancer patients with malignant ascites after gemcitabine failure.